-
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab’s (SLK) potential best-in-class and best-in-disease profile, with consistent responses that are higher than those observed in trials of competing agents at the end of their respective parental trials Namely, ~67% of patients treated with SLK…
-
CERAVE CELEBRATES OVER 100 AWARD-WINNING CONTENT CREATORS FROM 22 COUNTRIES FOR THE FIRST EVER GLOBAL CERAWARDS
The multi-day event united global creators in Hollywood for a content creation competition experience to educate and entertain consumers on healthy skin habits. NEW YORK, June 5, 2026 /PRNewswire/ — CeraVe, global skincare brand developed with dermatologists and recommended by more than 90,000 dermatologists worldwide1, brought together 111 award-winning creators from 22 countries for the…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
